Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland

por Çakar, Esra, Oniangue-Ndza, César, Schneider, Ralph P., Klijn, Sven L., Vogl, Ursula M., Rothermundt, Christian, May, Jessica R.
Publicado 2023

Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China

por Hu, Shanlian, Tang, Zhiliu, Harrison, James P., Hertel, Nadine, Penrod, John R., May, Jessica R., Juarez-Garcia, Ariadna, Holdgate, Orban
Publicado 2023

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advan...

por Mistry, Rohit, May, Jessica R., Suri, Gaurav, Young, Kate, Brixner, Diana, Oderda, Gary, Biskupiak, Joseph, Tang, Derek, Bhattacharyya, Subrata, Mishra, Dinesh, Bhattacharyya, Devarshi, Dalal, Anand A.
Publicado 2018

Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma

por Petersohn, Svenja, McGregor, Bradley, Klijn, Sven L, May, Jessica R, Ejzykowicz, Flavia, Kurt, Murat, Dyer, Matthew, Malcolm, Bill, Branchoux, Sébastien, Nickel, Katharina, George, Saby, Kroep, Sonja
Publicado 2023